Egyptian biotech startup Reme-D has secured a $500,000 investment from the Global Innovation Fund to expand its innovative PCR testing solutions across emerging markets.
Founded in 2022, the company develops room-temperature PCR kits that eliminate the need for cold-chain logistics—cutting diagnostic costs by up to 40% and improving accessibility in low-infrastructure regions.
Reme-D’s services include:
- Rapid PCR testing for infectious diseases
- Ongoing development in genetic, oncology, and maternal diagnostics
- Scalable solutions for healthcare systems and research institutions
The new funding will support production scale-up and regional expansion, with initial focus on markets such as Nigeria and Libya.
As noted by The Middle East Observer, the deal highlights rising investor confidence in Egypt’s biotech sector and the growing demand for cost-efficient, deployable diagnostic technologies in underserved regions.
